Lantheus Holdings Inc (LNTH) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Total Revenue Chart for Lantheus Holdings Inc

Lantheus Holdings Inc (LNTH) revenue for FY2025 was USD 1.5B, a 0.5% change from FY2024. Lantheus Holdings Inc's revenue grew from USD 356.3M in 2011 to USD 1.5B in 2025 (332.7% over 14 years). Earnings per share moved from USD -0.20 in 2014 to USD 0.40 in 2022. Revenue compound annual growth rate: 5-year CAGR of 35.3%, 10-year CAGR of 18.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$6.53B
Implied Share Price
$99.95
Enterprise Value
$6.56B
Revenue (TTM)
$1.56B
EBITDA
$392.22M
Profit Margin
17.69%
Trailing P/E
24.20
Forward P/E
14.27
Price/Book (MRQ)
4.98
Price/Sales (TTM)
4.19
EV/EBITDA
13.92
EV/Revenue
4.22
Dividend Yield
—
Book Value
$20.10
Free Cash Flow (FY2025)
$354.05M
Free Cash Flow Yield
5.42%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.